<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39412147</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1536-4844</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Inflammatory bowel diseases</Title><ISOAbbreviation>Inflamm Bowel Dis</ISOAbbreviation></Journal><ArticleTitle>Durable Immune Response and Long-term Efficacy of COVID-19 Vaccination in Children With Inflammatory Bowel Disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">izae225</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ibd/izae225</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Children with inflammatory bowel disease (IBD) may have diminished serologic response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and increased risk for subsequent severe coronavirus disease 2019 (COVID-19) infection. We sought to describe outcomes among those who developed SARS-CoV-2 infection following vaccination, characterize SARS-CoV-2 antibodies 1 year post-vaccination, and identify factors associated with durable serologic response.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We recruited children with IBD who received ≥2 doses of SARS-CoV-2 vaccine and prospectively collected data on (1) demographics, IBD characteristics, and therapy and (2) SARS-CoV-2 vaccination, testing, and infection symptoms. Serum was obtained for measurement of anti-receptor-binding domain IgG antibodies following a 2-part immunization at 12 and 52 weeks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We enrolled 298 participants (mean age 11.9 ± 3.82, 50% female, 67% Crohn's disease). Symptomatic COVID-19 infection after vaccination occurred in half of the participants, although only 2 (1%) required hospitalization. Anti-tumor necrosis factor alpha (TNF-α) was associated with higher likelihood of symptomatic COVID-19 infection, with an adjusted hazard ratio of 2.7 (95% CI, 1.5-5.0; P = .001). Nearly all participants (99%) had detectable antibody at Week 52. Children aged 1-5 years had lower 52-week antibody level compared to older children (P = .04), as did those on anti-TNF-α therapy (P = .007) and those who received only 2 vaccine doses prior to Week 52 (P &lt; .001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">SARS-CoV-2 vaccination provides lasting serologic response and protection against severe COVID-19 for most children with IBD, despite the use of lower vaccine doses in younger children and wide-ranging classes of immunosuppressive therapies.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of Crohn’s &amp; Colitis Foundation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kastl</LastName><ForeName>Arthur J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-2625-9390</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>Erica J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>Kimberly N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xian</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strople</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubinsky</LastName><ForeName>Marla C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Dr. Henry D. Janowitz Division of Gastroenterology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bousvaros</LastName><ForeName>Athos</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watkins</LastName><ForeName>Runa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology and Nutrition, University of Maryland School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Xiangfeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wenli</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cross</LastName><ForeName>Raymond K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higgins</LastName><ForeName>Peter D R</ForeName><Initials>PDR</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ungaro</LastName><ForeName>Ryan C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Dr. Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bewtra</LastName><ForeName>Meenakshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellaguarda</LastName><ForeName>Emanuelle A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farraye</LastName><ForeName>Francis A</ForeName><Initials>FA</Initials><Identifier Source="ORCID">0000-0001-6371-2441</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chun</LastName><ForeName>Kelly Y</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>Esoterix LabCorp,Calabasas, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zikry</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Esoterix LabCorp,Calabasas, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bastidas</LastName><ForeName>Monique</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Esoterix LabCorp,Calabasas, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Firestine</LastName><ForeName>Ann M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>Riley G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boccieri</LastName><ForeName>Margie E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Millie D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0001-5983-2758</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kappelman</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-0469-6856</Identifier><AffiliationInfo><Affiliation>Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Leona M. and Harry B. Helmsley Charitable Trust</Agency><Country /></Grant><Grant><Agency>Takeda Pharmaceuticals</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Inflamm Bowel Dis</MedlineTA><NlmUniqueID>9508162</NlmUniqueID><ISSNLinking>1078-0998</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>We demonstrate high rates of durable antibody response and low rates of coronavirus disease 2019-related hospitalization 1 year following severe acute respiratory syndrome coronavirus 2 vaccination in children with inflammatory bowel disease. Anti-tumor necrosis factor alpha therapy, young age, and fewer vaccine doses were associated with lower 52-week antibody level.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of Crohn’s &amp; Colitis Foundation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Crohn’s disease</Keyword><Keyword MajorTopicYN="N">humoral immune response</Keyword><Keyword MajorTopicYN="N">ulcerative colitis</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>8</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39412147</ArticleId><ArticleId IdType="doi">10.1093/ibd/izae225</ArticleId><ArticleId IdType="pii">7823564</ArticleId></ArticleIdList></PubmedData></PubmedArticle>